Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model.

Clinical lymphoma, myeloma & leukemia·2026
Same author

A plain language summary describing how talquetamab affects the way people with multiple myeloma feel and function in the MonumenTAL-1 study.

Future oncology (London, England)·2026
Same author

Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma.

JCI insight·2026
Same author

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

Blood advances·2026
Same author

Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab.

Haematologica·2026
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026

Related Experiment Video

Updated: Dec 30, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.8K

Selinexor for the treatment of multiple myeloma.

Klaus Podar1, Jatin Shah2, Ajai Chari3

  • 1Department of Internal Medicine, Karl Landsteiner University of Health Sciences, University Hospital, Krems, Austria.

Expert Opinion on Pharmacotherapy
|January 21, 2020
PubMed
Summary

Selinexor, a novel oral medication, offers a new treatment avenue for patients with penta-refractory multiple myeloma (MM) by inhibiting Exportin-1 (XPO-1). This Selective-Inhibitor-of-Nuclear-Export (SINE) compound represents a significant advance for heavily pretreated MM patients.

Keywords:
Multiple myelomaexportin-1penta-refractorinessselective inhibitor of nuclear export (sine) compounds

More Related Videos

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
06:29

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

5.9K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.1K

Related Experiment Videos

Last Updated: Dec 30, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.8K
Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
06:29

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

5.9K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.1K

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Multiple myeloma (MM) treatment resistance necessitates novel therapeutic strategies.
  • Exportin-1 (XPO-1) is a key nuclear export protein overexpressed in MM, driving disease progression.
  • Current therapies are insufficient for penta-refractory MM patients, highlighting an unmet clinical need.

Purpose of the Study:

  • To review the pathophysiologic role of XPO-1 in MM.
  • To summarize clinical data on selinexor, a Selective-Inhibitor-of-Nuclear-Export (SINE) compound, in combination therapies.
  • To discuss the safety, management, and future potential of selinexor in MM treatment.

Main Methods:

  • Literature review of XPO-1's role in MM.
  • Analysis of clinical trial data for selinexor in MM.
  • Synthesis of information on selinexor's safety profile and management.

Main Results:

  • Selinexor, in combination with dexamethasone, received FDA accelerated approval for penta-refractory MM.
  • Clinical data supports selinexor's efficacy in heavily pretreated MM patients.
  • Ongoing studies are exploring selinexor's use in earlier lines of MM therapy.

Conclusions:

  • Selinexor is a promising next-generation agent with a novel mechanism for treating advanced MM.
  • Further research is required to establish the long-term value of selinexor and other SINE compounds in MM treatment armamentarium.